Which countries are leading the battle in Biotech & Research?

Which countries are leading the battle in Biotech & Research?

Biotechnology is the incorporation of biology and technology for the production of environmental and human benefit goods and applications. According to MarketLine’s 2019 study

“”The biotechnology industry comprises drug development, processing and distribution, based on advanced research in biotechnology.””

Despite 48.2 per cent of the businesses in the sector located outside the U.S., the US is dominant in the market. Asia-Pacific companies hold 24% of the market, led by Europe (18.1%), and Middle East (1.8%) – the rest of the world is closing the remaining 7.9% of the market.

Ranking based on overall R&D expenditures for biotechnology

The number of companies is one way to identify biotech by region, while research and development expenses are another. The USA spends nearly 60 per cent of its closest rival, Japan, on R&D. Switzerland, France, Germany and Denmark are other significant expenses – each of which is about 10 per cent of the market.

Research and development are changing landscape

The EU, Japan and the United States have faced pressure in research and development budgets since 2008, with an average growth rate of just 1.7 per cent between 2014 and 2018. In the meantime, China’s total R&D investments have continued to rise by 9.1% from 2014 to 2018.

Public finances are still very tight in many countries and it is impossible, as was the case during the economic downturn in 2008-2010, to raise R&D budgets with public finance.


In 2010, the business panorama has tended to have looked more closely in several non-OECD countries in recent years, such as Singapore, Brazil, China, India and South Africa, according to the OECD science and technology survey.

Countries with the rank of various organizations

While Japan ranks second in other OECD metrics, according to other sources and parameters it doesn’t finish in the top five at all. Scientific American ranked in the 2016 Paradigm Scorecard in the top five biotech countries:

  1. America
  2. Singapore
  3. New Zealand
  4. Australia
  5. Denmark

These rankings were compiled using the following criteria:

  • intellectual property (IP) and the ability to protect it
  • intensity, recognized to be the effort in innovation; enterprise support—access to venture capital and business support
  • the education of and availability of an expert workforce
  • foundations such as infrastructure and the country’s R&D drivers
  • the country’s government, stability, and quality of regulation

Aim into the future

Countries with clear technological creation opportunities and different choices for accessing research funding are successful countries in the biotech industry.

Over and beyond borders: the World Biotechnology Report is a market report by Ernst & Young every year. This study showed in 2017 that 23 European biotech companies were made public, raising capital of $703 million while a Swiss group raised $76 million in an initial public offer (IPO) on a stand-alone basis.

Switzerland, Poland, the Netherlands, France, and Germany were also the countries in Europe that had companies raising capital via IPOs in 2017.

The combined $2.5 billion in capital raised by IPOs across China, Taiwan , Singapore, Japan and South Korea show a continued high interest in this rising market.

Although for both geographical areas the amount of funds raised by IPO has decreased from previous years, these statistics show that global biotechnology is an investment that continues to gain prominence and momentum.

Which countries are leading the battle in Biotech & Research?

Rajat Singhhttps://bioinformaticsindia.com
Rajat Singh is the chief Author at Bioinformatics India, he has been writing for the past 3 years and has a special interest in SEO, Technology, Health, Life Sciences and gaming.

Get in Touch

Related Articles

Get in Touch


Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest Posts